Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Biosciences Ltd. ( (AU:RHY) ) has provided an announcement.
Rhythm Biosciences has accelerated the commercial rollout of its ColoSTAT colorectal cancer blood test by activating its first commercial blood collection network through 4Cyte Pathology across major Australian cities. An initial 38 collection sites in Melbourne, Sydney and Brisbane now enable clinician referrals and patient access via established clinical pathways and the ColoSTAT Access Program.
The partnership leverages 4Cyte’s national pathology network and business development teams to build clinical awareness and drive test volumes at scale. Additional collection centres are being progressively activated and tracked through 4Cyte’s online platform, marking a pivotal step in ColoSTAT’s commercial journey and allowing Rhythm to focus on growing utilisation among primary care physicians and program participants.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple, affordable blood tests for the accurate and early detection of cancers. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes and reduce the global cancer burden through partnerships that support commercialisation and distribution of its diagnostic solutions.
Average Trading Volume: 950,004
Technical Sentiment Signal: Buy
Current Market Cap: A$72.76M
Find detailed analytics on RHY stock on TipRanks’ Stock Analysis page.